Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells

NCT07041801 PHASE1, PHASE2 RECRUITING

This study will investigate the safety and efficacy of allogeneic umbilical cord-derived stem cell therapy in treating patients with moderate to severe systemic lupus erythematosus.

Details

Lead sponsor	Shenzhen Beike Bio-Technology Co., Ltd.
Phase	PHASE1, PHASE2
Status	RECRUITING
Enrolment	58
Start date	Sat Jun 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 28 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Systemic Lupus Erythematosus (SLE)

Interventions

• hUC-MSCs treatment (low dose)
• hUC-MSCs treatment (medium dose)
• hUC-MSCs treatment (high dose)
• Placebo
• hUC-MSCs treatment （Double dose）

Countries

China